NYSE:APHA (Canada) Also trade in: Canada Germany UK

Aphria Inc

$ 6.83 -0.1 (-1.44%)
Volume: 2,332,033 Avg Vol (1m): 4,891,286
Market Cap $: 1.71 Bil Enterprise Value $: 1.69 Bil
P/E (TTM): 0.00 P/B: 1.35
Earnings Power Value -4.16
Net Current Asset Value -0.19
Tangible Book 1.86
Projected FCF 1.71
Median P/S Value 12.47
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.74
Cash-To-Debt ranked higher than
56.93% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
APHA: 1.74
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.74, Med: 10000, Max: 10000
Current: 1.74
1.74
10000
Equity-to-Asset 0.82
Equity-to-Asset ranked higher than
89.85% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
APHA: 0.82
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.82, Med: 0.89, Max: 0.97
Current: 0.82
0.82
0.97
Debt-to-Equity 0.05
Debt-to-Equity ranked higher than
89.77% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
APHA: 0.05
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.03, Med: 0.05, Max: 0.12
Current: 0.05
0.03
0.12
Debt-to-EBITDA -4.28
Debt-to-EBITDA ranked higher than
72.32% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
APHA: -4.28
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -4.28, Med: 2.86, Max: 5.02
Current: -4.28
-4.28
5.02
Piotroski F-Score 1
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.33
DISTRESS
GREY
SAFE
Beneish M-Score 2.17
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -4.96%
WACC 24.9%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -52.77
Operating Margin ranked lower than
75.91% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
APHA: -52.77
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1211.25, Med: -16.27, Max: 10.31
Current: -52.77
-1211.25
10.31
Net Margin % -30.90
Net Margin ranked higher than
98.63% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
APHA: -30.9
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1187.48, Med: 12.63, Max: 79.77
Current: -30.9
-1187.48
79.77
ROE % -2.74
ROE ranked lower than
52.40% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
APHA: -2.74
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -96.94, Med: -14.24, Max: 4.1
Current: -2.74
-96.94
4.1
ROA % -2.34
ROA ranked higher than
57.86% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
APHA: -2.34
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -90.39, Med: -13.75, Max: 3.61
Current: -2.34
-90.39
3.61
ROC (Joel Greenblatt) % -9.91
ROC (Joel Greenblatt) ranked higher than
66.20% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
APHA: -9.91
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -274.71, Med: 0.54, Max: 18.16
Current: -9.91
-274.71
18.16
3-Year Total Revenue Growth Rate 306.20
3-Year Revenue Growth Rate ranked higher than
99.42% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
APHA: 164.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 164.9
Current: 164.9
0
164.9

» APHA's 30-Y Financials

Financials (Next Earnings Date: 2019-07-15 Est.)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:APHA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 3741
Compare NAS:SUPN NAS:IRWD SZSE:300630 NAS:HRTX NAS:ENDP HKSE:02616 BOM:524494 TSX:HEXO TSE:4521 NAS:TCDA XLJU:KRKG SHSE:603567 NAS:PCRX SZSE:000078 SHSE:600062 SHSE:600267 SHSE:600329 HKSE:00867 SZSE:300725 HKSE:01558
Traded in other countries 10E.Germany 0UI4.UK
Address 245 Talbot Street W., Suite 103, Leamington, ON, CAN, N8H 1N8
Aphria Inc and its subsidiaries produce and sell medical marijuana. Its products include Capsules, Oral solutions, and Vaporizers. The company's operations are based in Leamington, Ontario. It is focused on producing and selling medical marijuana and its derivatives through retail sales and wholesale channels.

Ratios

Current vs industry vs history
Forward PE Ratio 185.19
Forward P/E ranked lower than
93.69% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
APHA: 185.19
Ranked among companies with meaningful Forward P/E only.
N/A
PB Ratio 1.35
PB Ratio ranked higher than
66.54% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
APHA: 1.35
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.92, Med: 3.29, Max: 8.66
Current: 1.35
0.92
8.66
PS Ratio 18.26
PS Ratio ranked lower than
91.74% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
APHA: 18.26
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 10.7, Med: 33.37, Max: 1200
Current: 18.26
10.7
1200
EV-to-EBIT -62.20
EV-to-EBIT ranked lower than
87.94% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
APHA: -62.2
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -152, Med: 35.8, Max: 507.4
Current: -62.2
-152
507.4
EV-to-EBITDA -124.65
EV-to-EBITDA ranked lower than
88.94% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
APHA: -124.65
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -185, Med: 38.9, Max: 9503.3
Current: -124.65
-185
9503.3
EV-to-Revenue 18.68
EV-to-Revenue ranked lower than
91.45% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
APHA: 18.68
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 9.5, Med: 35.4, Max: 1026.3
Current: 18.68
9.5
1026.3
Current Ratio 1.74
Current Ratio ranked higher than
73.45% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
APHA: 1.74
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.38, Med: 10.98, Max: 99.33
Current: 1.74
1.38
99.33
Quick Ratio 1.25
Quick Ratio ranked higher than
73.68% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
APHA: 1.25
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.25, Med: 10.37, Max: 99.33
Current: 1.25
1.25
99.33
Days Inventory 192.08
Days Inventory ranked lower than
96.69% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
APHA: 192.08
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 192.08, Med: 772.07, Max: 1294.77
Current: 192.08
192.08
1294.77
Days Sales Outstanding 133.63
Days Sales Outstanding ranked higher than
86.23% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
APHA: 133.63
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 14.75, Med: 33.48, Max: 133.63
Current: 133.63
14.75
133.63
Days Payable 617.85
Days Payable ranked lower than
99.08% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
APHA: 617.85
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 188.07, Med: 1052.52, Max: 2897.66
Current: 617.85
188.07
2897.66

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -58.80
3-Year Share Buyback Rate ranked lower than
88.27% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
APHA: -58.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -550, Med: -366.3, Max: -58.8
Current: -58.8
-550
-58.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.67
Price-to-Tangible-Book ranked lower than
65.55% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
APHA: 3.67
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.84, Med: 3.25, Max: 5.84
Current: 3.67
0.84
5.84
Price-to-Projected-FCF 3.99
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
79.14% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
APHA: 3.99
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.47, Med: 6.76, Max: 15.31
Current: 3.99
3.47
15.31
Price-to-Median-PS-Value 0.55
Price-to-Median-PS-Value ranked lower than
75.10% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
APHA: 0.55
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.32, Med: 1.02, Max: 29
Current: 0.55
0.32
29
Earnings Yield (Joel Greenblatt) % -1.60
Earnings Yield (Greenblatt) ranked lower than
58.02% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
APHA: -1.6
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -12.5, Med: 0.5, Max: 6.6
Current: -1.6
-12.5
6.6

More Statistics

Revenue (TTM) (Mil) $ 91.65
EPS (TTM) $ -0.13
Beta 3.81
Volatility % 94.07
52-Week Range $ 3.75 - 16.86
Shares Outstanding (Mil) 250.58

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 1
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N